The goal of this project is to demonstrate the feasibility of using ultrasound to temporarily make vascular tissue and cell membranes more permeable to deliver drug to vessel walls. EKOS has developed an ultrasound-catheter device for transmural drug delivery that may be useful in the treatment of restenosis following balloon angioplasty. Local ultrasound enhanced drug delivery may increase the usefulness of drugs that are too toxic or expensive to deliver systemically. The results of Phase I demonstrated that ultrasound can make eukaryotic cells permeable for the uptake of exogenous materials. The permeability was correlated with aspects of the acoustic signature radiated by the cavitation field in the cell suspension during exposure.
The aims of Phase II are to determine the effect of acoustic parameters on molecular uptake and cell viability in simple cell suspensions and more complex organized tissues and to develop a measure for the cavitation mediated permeability based on acoustic signature analysis. This measure will give a real time feedback predicting the bioeffects for optimizing therapy delivery.

Proposed Commercial Applications

The EKOS product will be an ultrasound catheter device that actively delivers drug into the artery wall for the treatment of restenosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44HL062024-03
Application #
6498983
Study Section
Special Emphasis Panel (ZRG1-SSS-X (24))
Program Officer
Skarlatos, Sonia
Project Start
1999-01-15
Project End
2005-01-31
Budget Start
2002-02-01
Budget End
2005-01-31
Support Year
3
Fiscal Year
2002
Total Cost
$331,168
Indirect Cost
Name
Ekos Corporation
Department
Type
DUNS #
City
Bothell
State
WA
Country
United States
Zip Code
98011